Innovating Works

IPL

Desconocido
ERA4TB: EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS INSTITUT PASTEUR DE LILLE FONDATION participó en un H2020 H2020-JTI-IMI2-2018-15-two-stage The European Regimen Accelerator for Tuberculosis (ERA4TB) has the explicit goal of developing a new combination therapy to treat all forms...
2019-12-12 - 2025-12-31 | Financiado
FAIR: FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG RESISTA... INSTITUT PASTEUR DE LILLE FONDATION participó en un H2020 H2020-SC1-BHC-2018-2020 Bacterial pneumonia is a leading cause of morbidity and mortality worldwide. Antibiotics constitute the standard of care but are faced with...
2019-12-06 - 2025-06-30 | Financiado
PERISCOPE: PERtussIS COrrelates of Protection Europe Sofia ref. 115910 INSTITUT PASTEUR DE LILLE FONDATION participó en un H2020 H2020-JTI-IMI2-2015-03-two-stage Pertussis vaccines have been very successful in reducing the global burden of pertussis-related disease. However, in the last decade there h...
2016-08-01 - 2022-08-31 | Financiado
ImmunoBile: Bile acid immune metabolism lipid and glucose homeostasis INSTITUT PASTEUR DE LILLE FONDATION participó en un H2020 ERC-2015-AdG The role of chronic inflammation in obesity, metabolic and cardiovascular diseases is increasingly recognized. Bile acids (BA), synthesized...
2016-06-28 - 2022-02-28 | Financiado
CoSTREAM: Common mechanisms and pathways in Stroke and Alzheimer s disease. INSTITUT PASTEUR DE LILLE FONDATION participó en un H2020 H2020-PHC-2014-2015 Common mechanisms and pathways in Stroke and Alzheimer's disease. It has long been recognized that stroke and (Alzheimer’s Disease) AD often...
2015-12-09 - 2021-05-31 | Financiado
TBVAC2020: TBVAC2020 Advancing novel and promising TB vaccine candidates from discovery to preclinical and ear... INSTITUT PASTEUR DE LILLE FONDATION participó en un H2020 H2020-PHC-2014-2015 The TBVAC2020 proposal builds on the highly successful and long-standing collaborations in subsequent EC-FP5-, FP6- and FP7-funded TB vaccin...
2014-12-03 - 2019-06-30 | Financiado
P16 AND METABOLISM: The role of p16INK4a in the development of obesity and insulin resistance INSTITUT PASTEUR DE LILLE FONDATION tramitó un FP7 Genome-wide association studies have linked the CDKN2A locus to an increased risk of Type 2 Diabetes (T2D), which is mostly accompanied by i...
Financiado
RESOLVE: A systems biology approach to RESOLVE the molecular pathology of two hallmarks of patients with meta... INSTITUT PASTEUR DE LILLE FONDATION participó en un FP7 Through combining basic pre-clinical and clinical research, network analysis and computational modelling, RESOLVE aims at resolving the dist...
Financiado
NEWTBVAC: Discovery and preclinical development of new generation tuberculosis vaccines INSTITUT PASTEUR DE LILLE FONDATION participó en un FP7 With 14.4 million prevalent cases and 1.7 million deaths tuberculosis (TB) remains one of the most serious infectious diseases to date. An e...
Financiado
HOMITB: Host and microbial molecular dissection of pathogenesis and immunity in tuberculosis INSTITUT PASTEUR DE LILLE FONDATION participó en un FP7 Tuberculosis (TB) is a leading public health problem. About half of the 10% of Mycobacterium tuberculosis-infected individuals develop overt...
Financiado
BIOMARCARE: Biomarker for Cardiovascular Risk Assessment in Europe INSTITUT PASTEUR DE LILLE FONDATION participó en un FP7 Biomarkers are considered as tools to enhance cardiovascular risk estimation. However, the value of biomarkers on risk estimation beyond Eur...
Financiado
NANOREG: A common European approach to the regulatory testing of nanomaterials INSTITUT PASTEUR DE LILLE FONDATION participó en un FP7 The innovative and economic potential of Manufactured Nano Materials (MNMs) is threatened by a limited understanding of the related EHS issu...
Financiado
TB PAN-NET: Pan European network for the study and clinical management of drug resistant tuberculosis INSTITUT PASTEUR DE LILLE FONDATION participó en un FP7 This proposal will establish an integrated and synergistic network to address the challenge of multiple drug resistant tuberculosis (MDR-TB)...
Financiado
THESCHISTOVAC: The targeted development of a new generation Vaccine for Schistosomiasis INSTITUT PASTEUR DE LILLE FONDATION participó en un FP7 The aim of this project is to develop a new generation vaccine for schistosomiasis. The vaccine will be based on exposed proteins and/or gly...
Financiado
AGEDBRAINSYSBIO: SYSTEMS BIOLOGY OF PATHWAYS INVOLVING BRAIN AGEING INSTITUT PASTEUR DE LILLE FONDATION participó en un FP7 In spite of valuable approaches applied to get a broad understanding of genetic, epidemiologic and molecular and system-level biological pri...
Financiado
HAIFREE: A Novel Filtration Technology Targeted at Enhancing the European Healthcare System s Efforts in Rest... At healthcare facilities, there is a strong demand for a new advanced air cleaning technology to prevent infectious diseases such as severe...
Financiado
TOBI: Targeting OBesity driven Inflammation INSTITUT PASTEUR DE LILLE FONDATION participó en un FP7 The TOBI project aims to analyse mechanisms provoking adipokine-mediated crosstalk and an inflammatory drift in obese patients. It will be t...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.